Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. [electronic resource]
Producer: 19970331Description: 1052-62 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antigens, CD
- Carcinoma, Renal Cell -- blood
- Double-Blind Method
- Female
- Humans
- Immunoglobulin G -- adverse effects
- Immunophenotyping
- Interleukin-2 -- adverse effects
- Kidney Neoplasms -- blood
- Male
- Melanoma -- blood
- Middle Aged
- Monocytes
- Receptors, Tumor Necrosis Factor
- Receptors, Tumor Necrosis Factor, Type II
- Recombinant Fusion Proteins -- adverse effects
- Skin Neoplasms -- blood
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.